Athersys tries to post-hoc-analyze its way out of another trial fail for stroke stem cell therapy
Athersys’ stem cell therapy has failed yet again.
In a 206-person trial conducted in Japan, Athersys’ stem cell therapy for stroke failed its primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
